Device Trial Radar · NCT02459054
Syncardia 50cc TAH-t as a Bridge to Transplant
Last checked: Nov 20, 2026Latest source record: Aug 10, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
16
Actual
Start
Oct 2015
Primary completion
Jul 29, 2020
Study completion Jul 29, 2020
Sponsor
- Lead sponsor
- SynCardia Systems. LLCNot on our public-company list
- Sponsor type
- Industry
- First posted
- Jun 1, 2015
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 10 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objective of the study is to evaluate whether the 50cc TAH-t can safely support, and provide probable benefit to, transplant-eligible pediatric patients (aged 10 - 18 years) and can safely and effectively support transplant-eligible adult patients (aged 19 - 75 years) at imminent risk of death from biventricular failure without experiencing permanent disabling, stroke-related deficits. The study will be conducted as a three-arm trial of the 50cc temporary Total Artificial Heart (TAH-t) as a bridge to transplant: * The Primary Pediatric Arm of the trial will evaluate the safety and probable benefit of the 50cc TAH-t for transplant-eligible patients 10 through 18 years of age. * The Primary Adult Arm of the trial will evaluate the safety and efficacy of the 50cc TAH-t for transplant-eligible patients 19 through 75 years of age. * The Secondary Arm will capture pediatric and adult subjects who did not meet enrollment criteria for a Primary Arm, but meet the less restrictive Secondary Arm enrollment criteria, in order to further characterize the use of the device.
Conditions
- Heart Failure, Right-Sided
- Cardiac Failure
- Heart Failure, Left-Sided
Interventions
SynCardia 50cc temporary Total Artificial Heart (TAH-t)Device
Replacement of both ventricles and all four valves with the investigational device as a bridge to transplantation.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Probable Benefit (for Pediatric Arm); Efficacy (for Adult Arm)Time frame: 6 months
Locations
26 sites in 1 country. Site status is shown where the registry gives one.
Banner University Medical Center
Tucson, Arizona
Cedars-Sinai Medical Center
Los Angeles, California
University of California Los Angeles
Los Angeles, California
23 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.